On April 29, Dan Ives of Wedbush Securities joined ‘Power Lunch’ on CNBC to discuss his outlook for the tech sector and expressed that tariffs aren’t stopping the AI revolution. According to Ives, the critical question for the sector was whether spending, particularly CapEx, was being maintained. He expressed confidence that CapEx was holding up and predicted that the forthcoming results from big tech companies would serve more as a confidence booster for the market, rather than fueling the existing fears. As some investors are of the idea that concerns about a potential soft patch in the economy remain, there’s a preference for safer investments in insurance and other stable sectors, rather than big tech. However, Ives acknowledged that while uncertainty had been prevalent in recent weeks, his own survey work and field research indicate that AI-related spending stays strong. He noted that, while there were areas of the cloud sector where spending was accelerating, the overall uncertainty would likely result in broad guidance ranges from companies.
Michael Darda, the Managing Director, Chief Economist, and Macrostrategist at ROTH, also believes that AI would generate solid returns in the future. Ives agreed with Darda’s assessment and stated that enterprises were seeing similar advancements and could not afford to leave their AI projects behind without the risk of consequently falling behind. He also pointed out that for companies like those in the MAG7, the AI revolution is a central theme, which is why challenges brought forward by tariffs would not impact the AI revolution as much. Darda changed his outlook from bearish to bullish on tech and AI recently due to his personal experience with AI tools, which he felt had improved over the past year.
Dan Ives reiterated that, despite the uncertainty created by tariffs, the demand for software remained a safety blanket, and spending by hyperscale companies is expected to continue. That being said, we’re here with a list of the 15 best growth stocks to buy for the next 3 years.
A hand holding a tablet revealing a financial dashboard of assets and stocks.
Our Methodology
We sifted through financial media reports to compile a list of the top growth stocks to buy for the next 3 years. We then selected 15 stocks with a 3-year revenue compound annual growth rate of over 20%. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024, which was sourced from Insider Monkey’s database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
15 Best Growth Stocks to Buy for the Next 3 Years
15. Corcept Therapeutics Inc. (NASDAQ:CORT)
3-Year Revenue CAGR: 22.64%
Number of Hedge Fund Holders: 29
Corcept Therapeutics Inc. (NASDAQ:CORT) discovers and develops medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US. The company’s primary revenue and growth driver is its Cushing’s syndrome franchise, which is centered around its drug called Korlym.
In 2024, the Cushing’s syndrome segment made $675 million in revenue, which was up 40% year-over-year. This came from a record number of new Korlym prescribers and patients throughout 2024, indicating increasing physician awareness of hypercortisolism’s prevalence. Corcept is solidifying its position in the Cushing’s syndrome market by developing and potentially launching relacorilant. This is a proprietary selective cortisol modulator.
Corcept submitted an NDA for relacorilant on December 30, 2024, based on compelling data from its Phase III GRACE and Phase II studies. These studies showed statistically significant improvements in hypertension, hyperglycemia, weight, and other Cushing’s symptoms, with a favorable safety profile. Corcept projects a 2025 revenue guidance of $900 to $950 million in this area.
ClearBridge Small Cap Strategy stated the following regarding Corcept Therapeutics Incorporated (NASDAQ:CORT) in its Q3 2024 investor letter:
“Another top contributor in health care, Corcept Therapeutics Incorporated (NASDAQ:CORT), saw its stock rise in the third quarter after strong earnings results and increased guidance for sales of Korlym, a hyperglycemia drug for adults with Cushing’s syndrome, which investors had been concerned would be vulnerable to the launch of a competitor’s generic version late last year. The company has seen added tailwinds from anticipation surrounding its next-generation version of the drug, which has fewer side effects, and is expected to release phase 3 data later this year and potentially file for FDA approval in 2025.”
14. Manhattan Associates Inc. (NASDAQ:MANH)
3-Year Revenue CAGR: 15.28%
Number of Hedge Fund Holders: 34
Manhattan Associates Inc. (NASDAQ:MANH) develops, sells, deploys, services, and maintains software solutions to manage supply chains, inventory, and omnichannel operations. For instance, it offers a warehouse management solution for managing goods and information across the distribution centers.
The company’s Cloud Revenue segment made $94 million in Q1 2025 revenue, which marked a year-over-year improvement of 21%. This was fueled by new customer acquisitions, where ~50% of new cloud bookings came from net new logos, and cross-selling the company’s unified product portfolio. Manhattan Associates is also undergoing the conversion of on-premise customers to cloud offerings.
The company is making continuing investments in product innovations, such as AI-powered features. For the full year 2025, Manhattan Associates Inc. (NASDAQ:MANH) projects Cloud revenue between $405 and $410 million. This growth is also expected to be driven by the expanding addressable market for cloud-based supply chain solutions.
Hedge Fund Resource Center